IP Watchdog

APRIL 8, 2025

Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision in Azurity Pharmaceuticals, Inc. affirming the District of Delawares ruling that Alkems generic drinkable antibiotic product did not infringe patent claims owned by Azurity Pharmaceuticals. Alkem Laboratories Ltd.

Pharmaceuticals 52

Pharmaceuticals Litigation 52

IP Watchdog

APRIL 16, 2025

While this years IP Index marked little movement among the top nations for IP legal frameworks, leaving the United States as the top nation overall for yet another year, stronger IP protections in Middle Eastern countries and efforts to weaken IP protections for pharmaceuticals in the EU and U.S.

Pharmaceuticals 59

Pharmaceuticals Technology 59

Securities Docket

OCTOBER 9, 2024

A former executive of a global pharmaceutical company pleaded guilty today in federal in Boston to earning more than $250,000 by trading on material non-public information. Gupta worked as the Director of Strategy and Operations in the Boston office of a global pharmaceutical company (Company A). District Court Judge Julia E.

Pharmaceuticals 52

Pharmaceuticals Pleadings 52

IP Watchdog

AUGUST 24, 2022

On August 19, British brand name pharmaceutical firm GlaxoSmithKline (GSK) filed a brief with the U.S. Supreme Court opposing a petition for writ of certiorari filed by generic drugmaker Teva Pharmaceuticals. Teva’s petition appeals a decision by the U.S.

Pharmaceuticals 126

Pharmaceuticals Litigation 126

Insurance Journal

JANUARY 27, 2025

is facing its first jury trial over claims the company wrongfully marketed its lucrative Gardasil cancer vaccine as safe, the latest high-stakes litigation for the pharmaceutical giant. Merck & Co. Lawyers for a Los Angeles woman will argue Monday that …

Pharmaceuticals 115

Pharmaceuticals Litigation 115

IP Watchdog

MARCH 9, 2022

The Initiative for Medicines, Access & Knowledge (I-MAK) has responded to a letter it received from Senator Thom Tillis (R-NC) in January asking the organization to address claims that its data on the effects of pharmaceutical patents on drug pricing is faulty. I-MAK’s view is that the U.S.

Pharmaceuticals 126

Pharmaceuticals 126

IP Watchdog

AUGUST 6, 2021

Court of Appeals for the Federal Circuit (CAFC) on Thursday underscored its October 2020 ruling that generic company, Teva Pharmaceuticals, was liable for induced infringement of GlaxoSmithKline’s (GSK’s) patent directed to a method of treating Congestive Heart Failure (CHF) using carvedilol.

Pharmaceuticals 124

Pharmaceuticals Litigation 124

IP Watchdog

MARCH 26, 2025

Senate Democratic Whip Dick Durbin (D-IL), Ranking Member of the Senate Judiciary Committee, and Senator Thom Tillis (R-NC), as well as Senators Chuck Grassley (R-IA), Chairman of the Senate Judiciary Committee, Chris Coons (D-DE), and Peter Welch (D-VT) this week reintroduced a bill titled The Interagency Patent Coordination and Improvement Act, which (..)

Pharmaceuticals 52

Pharmaceuticals 52

IP Watchdog

NOVEMBER 9, 2023

On October 7, the Federal Trade Commission (FTC) sent letters to 10 pharmaceutical companies notifying them of the agency’s intent to challenge allegedly improper patent listings in the U.S. Food and Drug Administration’s (FDA) Orange Book.

Pharmaceuticals 122

Pharmaceuticals 122

IP Watchdog

AUGUST 31, 2021

District Court for the Southern District of Florida ruled against plaintiff Vital Pharmaceuticals, Inc.’s In each of these opinions, the court noted the absence of survey evidence (or, in the Vital Pharmaceuticals case, the inadequacy of an “almost comically flawed” survey). On August 3, 2021, the U.S. On June 7, 2021, the U.S.

Case Law 126

Case Law Pharmaceuticals Evidence Litigation 126

IP Watchdog

JUNE 25, 2024

Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision today reversing a district court’s grant of Hikma Pharmaceuticals’ motion to dismiss Amarin Pharma, Inc.’s s complaint against it for induced infringement.

Pharmaceuticals 111

Pharmaceuticals Litigation 111

Insurance Journal

SEPTEMBER 3, 2024

decreased across the automotive, consumer product, food and drink, medical device and pharmaceutical industries in the second quarter, according to a new report from Sedgwick. Product recalls in the U.S. Sedgwick’s U.S. Recall Index found the 788 recalls across those …

Automotive 115

Automotive Pharmaceuticals 115

IP Watchdog

AUGUST 16, 2021

Court of Appeals for the Federal Circuit today issued two precedential decisions and one nonprecedential decision in cases involving Teva Pharmaceuticals and Eli Lilly, delivering wins and losses for each company.

Pharmaceuticals 119

Pharmaceuticals Litigation 119

Insurance Journal

OCTOBER 7, 2024

Supreme Court declined on Monday to hear former pharmaceutical company CEO Martin Shkreli’s challenge to a $64.6 million financial penalty imposed by a judge after he raised a lifesaving drug’s price by more than 4,000%. The justices turned …

Pharmaceuticals 102

Pharmaceuticals 102

IP Watchdog

SEPTEMBER 2, 2021

Court of Appeals for the Federal Circuit (CAFC) on Wednesday upheld a Delaware district court’s ruling that Belcher Pharmaceuticals Inc.’s In a precedential decision written by Judge Reyna, the U.S. s Chief Science Officer engaged in inequitable conduct, making its U.S. 9,283,197 unenforceable. Belcher brought the suit against Hospira, Inc.

Pharmaceuticals 134

Pharmaceuticals Litigation 134

IP Watchdog

NOVEMBER 6, 2023

Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision in Actelion Pharmaceuticals Ltd. Mylan Pharmaceuticals Inc. Today, the U.S. vacating an infringement judgment against Mylan in the Northern District of West Virginia.

Evidence 105

Evidence Pharmaceuticals Construction Litigation 105

IP Watchdog

JANUARY 24, 2023

Last week, Novartis Pharmaceuticals followed through on its September 2022 promise that it would appeal the U.S. Court of Appeals for the Federal Circuit’s (CAFC’s) June 2022 decision invalidating its patent for a dosing regimen for its multiple sclerosis drug Gilenya to the U.S.

Pharmaceuticals 124

Pharmaceuticals Litigation 124

IP Watchdog

JUNE 5, 2024

Chamber of Commerce’s Global Innovation Policy Center (GIPC), the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Council for Innovation Promotion (C4IP) are among a number of organizations that have recently submitted comments on the U.S.

Pharmaceuticals 113

Pharmaceuticals Manufacturing 113

IP Watchdog

NOVEMBER 13, 2024

The petition was filed on September 11, 2024, by Salix Pharmaceuticals and stems from an April 2024 precedential decision of the Federal Circuit affirming a district court’s final judgment that certain claims of several patents owned by Salix for a drug used to treat irritable bowel syndrome (IBS) and other ailments were invalid as obvious.

Pharmaceuticals 59

Pharmaceuticals Litigation 59

IP Watchdog

FEBRUARY 1, 2022

Just over one week ago, Professor Adam Mossoff of the Antonin Scalia Law School at George Mason University published a Policy Memo with the Hudson Institute charging that some of the key data relied upon in the heated debate over the effects of pharmaceutical patents on drug pricing and access may be faulty.

Pharmaceuticals 122

Pharmaceuticals 122

IP Watchdog

MARCH 7, 2025

International Trade Commissions economic prong analysis for the domestic industry requirement of Section 337, finding that petitioners at the Patent Trial and Appeal Board have no self-executing discovery obligations to present evidence from parallel ITC proceedings, and more; strong global demand for AI chips buoys Broadcoms first quarter results; (..)

Discovery 52

Discovery Pharmaceuticals Evidence 52

IP Watchdog

JULY 29, 2021

Earlier today, the Senate Judiciary Committee held an Executive Business Meeting in which the Committee discussed and favorably reported four bills aimed at reducing prescription drug prices for consumers and curbing perceived abuses of the patent system by brand pharmaceutical companies.

Pharmaceuticals 122

Pharmaceuticals Manufacturing Litigation 122

IP Watchdog

APRIL 5, 2022

Patent and Trademark Office (USPTO) to once again voice his concerns about several sources advancing data on the effects of pharmaceutical patents on drug pricing. On Friday, April 1, Senator Thom Tillis (R-NC) wrote to the Food and Drug Administration (FDA) and the U.S.

Pharmaceuticals 126

Pharmaceuticals 126

IP Watchdog

SEPTEMBER 30, 2022

Court of Appeals for the Federal Circuit (CAFC) earlier today upheld a Patent Trial and Appeal Board (PTAB) decision finding that Mylan Pharmaceuticals, Inc. In its third precedential patent opinion this week, the U.S. failed to show that certain claims of Merck Sharp & Dohme Corp.’s

Pharmaceuticals 122

Pharmaceuticals Litigation 122

Insurance Journal

APRIL 9, 2025

Jazz Pharmaceuticals JAZZ.O said on Tuesday that it had agreed to a settlement of $145 million to resolve a series of antitrust lawsuits related to its narcolepsy drug, Xyrem. Xyrem, a medication approved in the U.S., is used for the …

Pharmaceuticals 92

Pharmaceuticals 92

IP Watchdog

MARCH 21, 2025

This week in Barks & Bites: American pharmaceutical firm Johnson & Johnson announces $55 billion in U.S. by BOE Technology.

Pharmaceuticals 52

Pharmaceuticals Construction Litigation Technology 52

Insurance Journal

NOVEMBER 14, 2024

A jury has awarded the city of Baltimore $266 million in damages in its suit against pharmaceutical firms McKesson and AmerisourceBergen for their part in the city’s opioid epidemic. With the jury award, the city has notched another win for …

Pharmaceuticals 103

Pharmaceuticals 103

IP Watchdog

APRIL 3, 2023

The Information Technology and Innovation Foundation (ITIF) is hosting an event on the downfall of Japan’s pharmaceutical industry. This week in Washington IP news, Congress is out of town thanks to a state work period, but there are still several interesting events related to the IP world.

Pharmaceuticals 59

Pharmaceuticals Technology 59

IP Watchdog

NOVEMBER 8, 2021

Mylan Pharmaceuticals Inc. On November 5, the U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision in Celgene Corp.

Pharmaceuticals 110

Pharmaceuticals Pleadings Litigation 110

IP Watchdog

FEBRUARY 2, 2023

The key data being questioned is that of the Initiative for Medicines, Access & Knowledge (I-MAK), an advocacy organization that has become a “principal, go-to source” for data on the number of patents and patent applications covering pharmaceutical innovations.

Pharmaceuticals 119

Pharmaceuticals Technology 119

IP Watchdog

SEPTEMBER 22, 2022

Novartis Pharmaceuticals announced today that it will appeal the U.S. Court of Appeals for the Federal Circuit’s (CAFC’s) June decision invalidating its patent for a dosing regimen for its multiple sclerosis drug Gilenya to the U.S. Supreme Court, after the CAFC denied its request to rehear the case.

Pharmaceuticals 119

Pharmaceuticals Litigation 119

Insurance Journal

DECEMBER 12, 2024

COLUMBUS, Ohio (AP) The Ohio Supreme Court ruled last Tuesday that the state’s product liability law prohibits counties from bringing public nuisance claims against national pharmaceutical chains as they did as part of national opioid litigation, a decision that …

Pharmaceuticals 98

Pharmaceuticals Court Rules Litigation 98

IP Watchdog

JULY 21, 2022

Mylan Pharmaceuticals Inc. Last week, the U.S. Supreme Court received several amicus briefs filed in support of the petition for writ of certiorari filed in Biogen International GmbH v. If cert is granted, this case will ask the nation’s highest court to clarify the written description requirement under 35 U.S.C. §

Pharmaceuticals 105

Pharmaceuticals Litigation 105

IP Watchdog

MARCH 30, 2023

Solicitor General on Wednesday filed an amicus brief with the United States Supreme Court advising it to grant Teva Pharmaceuticals’ petition for writ of certiorari relating to generic manufacturers’ liability for infringement through the use of “skinny labels” on generic drugs. The SG’s brief said that the U.S.

Pharmaceuticals 115

Pharmaceuticals Manufacturing Litigation 115

IP Watchdog

AUGUST 14, 2021

In the Report, the Committee pointed out the “challenges in strengthening the country’s IPR regime, the related procedural and substantive constraints, legal aspects and other issues, such as low awareness of IPR, counterfeiting and piracy, IP financing, and IPRs in agriculture and pharmaceutical sector, etc.”.

Pharmaceuticals 130

Pharmaceuticals Technology 130

IP Watchdog

MAY 12, 2023

This week in Other Barks & Bites: AI inventorship comments due, the United States Patent and Trademark Office (USPTO) seeks nominations to two advisory committees; Oprah’s company settles a trademark dispute with a podcast; and high-profile pharmaceutical company CEOs testify before the Senate on insulin prices.

Pharmaceuticals 102

Pharmaceuticals 102

Insurance Journal

DECEMBER 2, 2024

The province of British Columbia can bring a class action lawsuit against pharmaceutical companies for opioid harms on behalf of multiple governments across Canada, the country’s Supreme Court ruled on Friday. In 2018, BC sued more than 40 drug manufacturers, …

Pharmaceuticals 92

Pharmaceuticals Manufacturing Court Rules Litigation 92